Latest Breaking News On - Bernard ronchi - Page 1 : vimarsana.com

CSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

CSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New zealandNordrhein westfalenUnited kingdomDemyelinating polyneuropathyBernard ronchiPaul mckenzieStephen mckeonVifor pharmaJimmy bakerJapan ministry of healthExecutive officerManaging directorImmune globulin intravenousImmune globulin subcutaneousPrimary immune deficiencySecondary immune deficiency

Half year reported NPATA US$2 billion, Up 13% at constant currency

Half year reported NPATA US$2 billion, Up 13% at constant currency
singaporestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from singaporestar.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew zealandPaul mckenzieBernard ronchiVifor pharmaJimmy bakerStephen mckeonDemyelinating polyneuropathyJapan ministry of healthExecutive officerManaging directorImmune globulin intravenousImmune globulin subcutaneousPrimary immune deficiencySecondary immune deficiencyChronic inflammatory demyelinating polyneuropathy

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS4 Revenue $8.05 billion, up 11% at CC3NPAT $1.90 billion1, up 17%NPAT $1.94 billion1 at CC3, up 20%NPATA $2.02 billion1,2 , up.

United kingdomNew zealandStephen mckeonBernard ronchiPaul mckenzieDemyelinating polyneuropathyVifor pharmaJimmy bakerJapan ministry of healthExecutive officerManaging directorImmune globulin intravenousImmune globulin subcutaneousPrimary immune deficiencySecondary immune deficiencyChronic inflammatory demyelinating polyneuropathy